Dr Saad Highlights Results Following the ACIS Study

Fred Saad, MD, University of Montreal Hospital Center, discusses the findings of ACIS, a placebo-controlled, phase 3 clinical trial of apalutamide and abiraterone acetate plus prednisone versus abiraterone alone for chemotherapy-naive castration-resistant prostate cancer (CRPC).